C. We´ber et al. / Tetrahedron Letters 43 (2002) 2971–2974
2973
Table 1.
Entry
Compound
NR1R2
R3
Yield (%)a
Purity (%)b
1
2
3
4
5
6
7
8
9
7a
7b
7c
7d
7e
6a
6b
6c
6d
Piperidin-1-yl
–
–
–
–
75
69
74
–
99
94
88
15
12
97
98
92
96
Morpholin-4-yl
Bis(n-butyl)amino
n-Hexylamino
N-Methylphenylamino
Piperidin-1-yl
Piperidin-1-yl
Piperidin-1-yl
Piperidin-1-yl
–
–
Methyl
Ethyl
Isopropyl
2-Methylbutyl
57
71
67
62
a The overall yield was determined by weight based on the loading of 2. The yields refer to compounds purified by flash chromatography.
b The purities of the crude products were determined by HPLC–MS at 254 nm. The structures of the purified products were confirmed by 1H
NMR and MS spectroscopy. Compound 7a: 1H NMR (DMSO-d6, TMS) l 1.50–1.78 (br m, 6H), 3.58–3.70 (br m, 4H), 7.21 (dd, 1H, J=8.9 Hz
and 2.6 Hz), 7.28 (d, 1H, J=2.6 Hz), 7.40 (d, 1H, J=8.9 Hz), 9.94 (br s, 1H); MS (EI) 245 (M+). Compound 7b: 1H NMR (DMSO-d6, TMS)
l 3.69–3.84 (br m, 8H), 7.29 (dd, 1H, J=9.0 Hz and 3.0 Hz), 7.34 (d, 1H, J=3.0 Hz), 7.81 (d, 1H, J=9.0 Hz), 10.20 (br s, 1H); MS (EI) 247
(M+). Compound 7c: 1H NMR (DMSO-d6, TMS) l 0.91 (t, 6H, J=7.2 Hz), 1.26–1.40 (m, 4H), 1.49–1.62 (m, 4H), 3.55 (t, 4H, J=7.5 Hz), 7.20
(dd, 1H, J=9.0 Hz and 3.0 Hz), 7.28 (d, 1H, J=3.0 Hz), 7.44 (d, 1H, J=9.0 Hz), 9.82 (br s, 1H); MS (EI) 289 (M+). Compound 7d: MS (EI)
261 (M+). Compound 7e: MS (EI) 267 (M+). Compound 6a: 1H NMR (MeOH-d4, TMS) l 1.70–1.85 (br m, 6H), 3.70–3.80 (br m, 4H), 3.89 (s,
3H), 7.41 (dd, 1H, J=9.0 Hz and 2.7 Hz), 7.50–7.56 (m, 2H); MS (EI) 259 (M+). Compound 6b: 1H NMR (DMSO-d6, TMS) l 1.34 (t, 3H, J=6.9
Hz), 1.48–1.66 (br m, 6H), 3.49–3.60 (br m, 4H), 4.05 (q, 2H, J=6.9 Hz), 7.15–34 (m, 3H), 11.23 (s, 1H); MS (EI) 273(M+). Compound 6c: 1H
NMR (DMSO-d6, TMS) l 1.28 (d, 6H, J=6.0 Hz), 1.46–1.68 (br m, 6H), 3.50–3.62 (br m, 4H), 4.54–4.68 (m, 1H), 7.11–7.34 (m, 3H), 11.22
(s, 1H); MS (EI) 287 (M+). Compound 6d: 1H NMR (MeOH-d4, TMS) l 0.98 (t, 3H, J=7.2 Hz), 1.04 (d, 3H, J=6.6 Hz), 1.22–1.36 (m, 1H),
1.52–1.78 (m, 7H), 1.78–1.97 (m, 1H), 3.60–3.74 (m, 4H), 3.76–3.92 (m, 2H), 7.24 (dd, 1H, J=9.0 Hz and 3.0 Hz), 7.35 (d, 1H, J=9.0 Hz), 7.46
(d, 1H, J=3.0 Hz); MS (EI) 315 (M+).
Our approach is especially attractive for combinatorial
synthesis due to the wide range of commercially avail-
able alcohols and secondary amines which can be used
as diversity elements. Considering the fact that it is the
enol–ether form of 4(3H)-quinazolinone that is coupled
to solid support allows us to use Mitsunobu conditions
without alkylation of N-3 or C4-O.
Eur. J. Med. Chem. 1984, 19, 381–383.
6. Xia, Y.; Yang, Z.-Y.; Hour, M.-J.; Kuo, S.-C.; Xia, P.;
Bastow, K. F.; Nakanishi, Y.; Nampoothiri, P.; Hackl,
T.; Hamel, E.; Lee, K.-H. Bioorg. Med. Chem. Lett. 2001,
11, 1193–1196.
7. Chao, Q.; Deng, L.; Shih, H.; Leoni, L. M.; Genini, D.;
Carson, D. A.; Cottam, H. B. J. Med. Chem. 1999, 42,
3860–3872.
In summary, we have developed a new solid-phase
method for the synthesis of 2,6-disubstituted-4(3H)-
quinazolinones. Simple and mild reaction conditions
and the huge number of commercially available build-
ing blocks permit us to synthesize large combinatorial
libraries.
8. Bhaduri, A. P.; Garg, N. K.; Nukherje, S. K. Indian J.
Biochem. 1975, 12, 413–414.
9. Majer, J. P.; Lewis, G. S.; Curtis, M. J.; Zhang, J.
Tetrahedron Lett. 1997, 38, 8445–8452.
10. Villalgordo, J. M.; Obrecht, D.; Chucholowsky, A. Syn-
lett 1998, 1405–1407.
11. Gopalsamy, A.; Yang, H. J. Comb. Chem. 2000, 378–381.
12. Yang, R.-Y.; Kaplan, A. Tetrahedron Lett. 2000, 41,
7005–7008.
13. Gustafson, G. R.; Baldino, C. M.; O’Donnell, M.-M. E.;
Sheldon, A.; Tarsa, R. J. Tetrahedron 1998, 54, 4051–
4065.
Acknowledgements
´
We wish to thank Ada´m Demeter for NMR and Ga´bor
Czira for MS analyses of our products.
14. Masquelin, T.; Meunier, N.; Gerber, F.; Rosse, G. Hete-
rocycles 1998, 48, 2489–2505.
15. Baxter, A. D.; Boyd, E. A.; Cox, P. B.; Loh, V., Jr.;
Monteils, C.; Proud, A. Tetrahedron Lett. 2000, 41, 8177–
8181.
References
16. Kyung, H. Y.; Sung, E. K.; Kye, J. S.; Dong, C. K.;
Sang, W. P.; Dong, J. K. Synth. Commun. 2001, 31,
835–840.
1. Nobuo, O.; Toshihiko, Y.; Takayuki, A.; Eiichi, K.;
Hideo, K.; Yasuo, I. Chem. Pharm. Bull. 1988, 36, 2955–
2967.
17. Brill, W. K.-D.; Riva-Toniolo, C. Tetrahedron Lett. 2001,
42, 6515–6518.
18. Fiorini, M. T.; Abell, C. Tetrahedron Lett. 1998, 39,
1827–1830.
2. Kung, P.-P.; Casper, M. D.; Cook, K. L.; Wilson-Lin-
gardo, L. J. Med. Chem. 1999, 42, 4705–4713.
3. Hess, H. J.; Cronin, T. H.; Scriabine, A. J. Med. Chem.
1968, 11, 130–136.
19. Dorff, P. H.; Garigipati, R. S. Tetrahedron Lett. 2001, 42,
2771–2773.
20. Froelicher, V.; Cohen, J. B. J. Chem. Soc. 1921, 119,
1425–1432.
4. Gauss, W.; Kabbe, H. J.; Paulus, W.; Rosslenbroich, H.
J.; Brandes, W. 1984, Ger. Offen. DE 341080, Chem.
Abstr. 104. P 64209y.
5. Mannschreck, A.; Koller, H.; Stuhler, G.; Davies, M. A.